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Abstract
Background
The surveillance of drug resistance among tuberculosis (TB) patients is central to com-
batting the global TB epidemic and preventing the spread of antimicrobial resistance. Isonia-
zid and rifampicin are two of the most powerful first-line anti-TB medicines, and resistance
to either of them increases the risk of treatment failure, relapse, or acquisition of resistance
to other drugs. The global prevalence of rifampicin resistance is well documented, occurring
in 3.4% (95% CI 2.5%–4.4%) of new TB patients and 18% (95% CI 7.6%–31%) of previously
treated TB patients in 2018, whereas the prevalence of isoniazid resistance at global and
regional levels is less understood. In 2018, the World Health Organization (WHO) recom-
mended a modified 6-month treatment regimen for people with isoniazid-resistant, rifampi-
cin-susceptible TB (Hr-TB), which includes rifampicin, pyrazinamide, ethambutol, and
levofloxacin. We estimated the global prevalence of Hr-TB among TB patients and investi-
gated associated phenotypic and genotypic drug resistance patterns.
Methods and findings
Aggregated drug resistance data reported to WHO from either routine continuous surveil-
lance or nationally representative periodic surveys of TB patients for the period 2003–2017
were reviewed. Isoniazid data were available from 156 countries or territories for 211,753
patients. Among these, the global prevalence of Hr-TB was 7.4% (95% CI 6.5%–8.4%)
among new TB patients and 11.4% (95% CI 9.4%–13.4%) among previously treated TB
patients. Additional data on pyrazinamide and levofloxacin resistance were available from 6
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003008 January 21, 2020 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Dean AS, Zignol M, Cabibbe AM, Falzon
D, Glaziou P, Cirillo DM, et al. (2020) Prevalence
and genetic profiles of isoniazid resistance in
tuberculosis patients: A multicountry analysis of
cross-sectional data. PLoS Med 17(1): e1003008.
https://doi.org/10.1371/journal.pmed.1003008
Academic Editor: Madhukar Pai, McGill University,
CANADA
Received: June 28, 2019
Accepted: December 5, 2019
Published: January 21, 2020
Copyright: © 2020 World Health Organization.
Licensee Public Library of Science. This is an open
access article distributed under the Creative
Commons Attribution IGO License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly
cited. //creativecommons.org/licenses/by/3.0/igo/.
In any use of this article, there should be no
suggestion that WHO endorses any specific
organization, products or services. The use of the
WHO logo is not permitted. This notice should be
preserved along with the article’s original URL.
Data Availability Statement: All relevant data are
provided as Supporting Information files (S1 Data
file and S3 Data file). Additional related whole
genome sequencing data are available on the
Sequence Read Archive of the National Center for
Biotechnology Information as recalibrated BAM
countries (Azerbaijan, Bangladesh, Belarus, Pakistan, the Philippines, and South Africa).
There were no cases of resistance to both pyrazinamide and levofloxacin among Hr-TB
patients, except for the Philippines (1.8%, 95% CI 0.2–6.4) and Belarus (5.3%, 95% CI 0.1–
26.0). Sequencing data for all genomic regions involved in isoniazid resistance were avail-
able for 4,563 patients. Among the 1,174 isolates that were resistant by either phenotypic
testing or sequencing, 78.6% (95% CI 76.1%–80.9%) had resistance-conferring mutations
in the katG gene and 14.6% (95% CI 12.7%–16.8%) in both katG and the inhA promoter
region. For 6.8% (95% CI 5.4%–8.4%) of patients, mutations occurred in the inhA promoter
alone, for whom an increased dose of isoniazid may be considered. The main limitations of
this study are that most analyses were performed at the national rather than individual
patient level and that the quality of laboratory testing may vary between countries.
Conclusions
In this study, the prevalence of Hr-TB among TB patients was higher than the prevalence of
rifampicin resistance globally. Many patients with Hr-TB would be missed by current diag-
nostic algorithms driven by rifampicin testing, highlighting the need for new rapid molecular
technologies to ensure access to appropriate treatment and care. The low prevalence of
resistance to pyrazinamide and fluoroquinolones among patients with Hr-TB provides fur-
ther justification for the recommended modified treatment regimen.
Author summary
Why was this study done?
• Tuberculosis (TB) is the leading cause of death from an infectious disease, with 1.2 mil-
lion deaths occurring in 2018.
• People infected with a TB strain that is resistant to standard medicines used for treat-
ment, including rifampicin or isoniazid, have a lower chance of being cured and a
higher risk of death.
• In 2018, the World Health Organization (WHO) recommended a modified treatment
regimen for patients with TB that is resistant to isoniazid but susceptible to rifampicin
(Hr-TB).
What did the researchers do and find?
• Data reported from 156 countries or territories to WHO between 2002 and 2018 were
used to determine that a relatively high proportion of TB patients had Hr-TB: 7.4%
(95% CI 6.5%–8.4%) of new patients and 11.4% (95% CI 9.4%–13.4%) of previously
treated patients.
• In 6 countries with testing results for other medicines that are recommended in the
modified treatment regimen (pyrazinamide and levofloxacin), resistance among Hr-TB
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patients was uncommon. Combined resistance to both drugs was only detected in the
Philippines and Belarus but not in Azerbaijan, Bangladesh, Pakistan, or South Africa.
• Data from whole genome sequencing were also used to investigate markers of isoniazid
resistance in 6 countries (Azerbaijan, Belarus, Bangladesh, Pakistan, South Africa and
Ukraine).
What do these findings mean?
• The modified treatment regimen recommended by WHO in 2018 for Hr-TB patients is
likely to be effective in many settings.
• However, many patients with Hr-TB are missed because of the lack of laboratory capac-
ity in many countries to screen for isoniazid resistance and the absence of appropriate
diagnostic tools.
Introduction
In 2018, an estimated 10 million people developed tuberculosis (TB) globally, and TB was the
leading cause of death from a single infectious agent with an estimated 1.2 million deaths [1].
The surveillance of drug resistance among TB patients is central to combatting the global TB
epidemic and preventing the spread of antimicrobial resistance. Surveillance data can be used
to guide the planning of TB diagnostic and treatment services, design appropriate treatment
regimens, and monitor the effectiveness of interventions.
The Global Project on Anti-TB Drug Resistance Surveillance, hosted by the World Health
Organization (WHO), is the oldest and largest antimicrobial resistance surveillance project in
the world [2]. Since its launch in 1994, data on drug resistance among TB patients have been
systematically collected and analysed from 164 countries worldwide, collectively accounting
for more than 99% of the world’s population and TB patients. This includes 105 countries that
have continuous surveillance systems based on routine diagnostic drug susceptibility testing of
most TB patients and 59 countries that rely on periodic epidemiological surveys of nationally
representative samples of patients.
Rifampicin-resistant TB requires treatment with a second-line treatment regimen [3].
Using data from the Global Project, 3.4% (95% CI 2.5%–4.4%) of new TB cases and 18% (95%
CI 7.6%–31%) of previously treated TB cases were estimated to have rifampicin-resistant TB in
2018. This includes multidrug-resistant (MDR)-TB, which is defined as resistance to both
rifampicin and isoniazid. In 2018, 484,000 incident cases of rifampicin-resistant TB were esti-
mated to have occurred worldwide [1].
Together with rifampicin, isoniazid is one of the most powerful drugs for the treatment of
TB. These 2 drugs represent the cornerstone of the first-line treatment regimen recommended
by WHO and used worldwide [4]. It is also a component of both shorter and longer second-
line treatment regimens for rifampicin-resistant TB [3]. Isoniazid is critical not only to the
treatment of active TB, but it is also the most commonly used medicine for preventive therapy
[5,6].
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Concerningly, a recent systematic review of published literature revealed that treatment of
isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) with the standard first-line regimen for
new TB patients resulted in 11% (95% CI 6%–17%) treatment failure, compared with 2% (95%
CI 1%–3%) among drug-susceptible TB patients [7]. To increase the likelihood of long-term
cure of TB patients, WHO released updated guidance for the treatment of patients with Hr-TB
in 2018 [8]. The main regimen is a 6-month course of rifampicin, pyrazinamide, ethambutol,
and levofloxacin. The addition of a higher dose of isoniazid may be considered if only low-
level isoniazid resistance is present, as indicated by specific inhA promoter mutations in the
absence of katG mutations.
In this article, we describe the global prevalence of Hr-TB, with and without resistance to
other anti-TB medicines critical for its treatment, and molecular markers of isoniazid resis-
tance. We also discuss the implications of our findings for TB diagnosis, treatment, and care.
Methods
Study population
This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guideline (S1 STROBE Checklist). While no prospective protocol was
developed, the analysis was conducted in line with standard methodology used to generate the
prevalence estimates that are presented each year in WHO’s Global TB Report [1]. The analysis
was conducted following release of the 2018 edition of the Global TB Report in October 2018
[9].
Aggregated data—from either routine continuous surveillance or national representative
periodic surveys—on the proportions of new and previously treated cases with resistance to
rifampicin and isoniazid are reported annually by countries to WHO. For surveillance data to
be considered nationally representative, at least 80% of notified cases of pulmonary labora-
tory-confirmed TB must have a documented test result for drug susceptibility for at least
rifampicin [1]. Countries without such continuous surveillance systems rely on nationally rep-
resentative periodic surveys to estimate the burden of drug-resistant TB, for which methods
are described elsewhere [10]. The focus of these surveys is the measurement of resistance to
rifampicin and isoniazid, although data on resistance to other drugs may also be collected.
For 6 countries in which surveys were conducted between 2010 and 2014, representative
data on resistance to pyrazinamide and fluoroquinolones were also available for both new and
previously treated Hr-TB patients. Details of these surveys are provided elsewhere [11]. The 6
countries represented a range of programmatic and epidemiological settings and included
Azerbaijan [12], Bangladesh [13], Belarus (city of Minsk) [14], Pakistan [15], the Philippines
[16], and South Africa (Gauteng and Kwazulu Natal provinces) [17]. Data on molecular mark-
ers of isoniazid resistance were also available from these countries, as well as for Ukraine [18].
For each survey, ethical approval and written informed consent from patients was obtained
(S1 Text).
Laboratory analyses
Isoniazid and rifampicin. Testing for isoniazid and rifampicin in surveys and continuous
surveillance uses either molecular or phenotypic methods. For the 7 countries mentioned, cul-
ture isolates from enrolled patients were tested using phenotypic methods according to the
most recent WHO recommendations at the time [19], by either the Lo¨wenstein-Jensen pro-
portion method (Azerbaijan, Bangladesh, Pakistan, the Philippines, and Ukraine) or MGIT
960 (Becton Dickinson, Sparks, MD, US; Belarus and South Africa) at the following
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concentrations: 0.2 mg/mL isoniazid and 40.0 mg/L rifampicin on Lo¨wenstein-Jensen medium
and 0.1 mg/mL isoniazid and 1.0 mg/L rifampicin on MGIT 960.
Fluoroquinolones. Testing for fluoroquinolones (moxifloxacin and levofloxacin) was
done using phenotypic methods according to the most recent WHO recommendations at the
time [19]. For 5 countries (Azerbaijan, Bangladesh, Belarus, Pakistan, and South Africa), all
isolates were tested for moxifloxacin at 0.5 mg/L using MGIT 960. Isolates that were resistant
to moxifloxacin were tested for resistance to levofloxacin at 1.5 mg/L using MGIT 960. Isolates
that were susceptible to moxifloxacin at 0.5 mg/mL were assumed to be susceptible to levoflox-
acin at 1.5 mg/L. For the Philippines, drug susceptibility testing was performed on a randomly
selected subset of isolates for levofloxacin at 1.5 mg/L using MGIT 960. Drug susceptibility
testing for levofloxacin was not performed for Ukraine.
Sequencing. Whole genome sequencing was performed for 6 countries (Azerbaijan, Ban-
gladesh, Belarus, South Africa, Ukraine, and a subset of isolates from Pakistan). Illumina tech-
nology (Illumina, San Diego, CA, US) was used for all countries except for Belarus, where Ion
Torrent technology (Thermo Fisher Scientific, MA, US) was used. The following extended
promoter and/or coding regions were considered for isoniazid: ahpC (Rv2428), ahpC
upstream, fabG, inhA, inhA promoter (Rv1483, fabG1 upstream region), katG, furA (Rv1909c),
and furA upstream. Targeted gene sequencing was performed for 2 countries (the Philippines
and most of the Pakistan isolates) using Sanger technology (Thermo Fisher Scientific) for the
relevant regions of inhA (locus Rv1484), inhA promoter, and katG (Rv1908c) genes. For pyra-
zinamide, the pncA (Rv2043c) gene was considered. For fluoroquinolones, the gyrA and gyrB
genes were considered.
An established framework was used for the classification of detected mutations according
to the confidence with which they are associated with drug resistance [20]. Mutations classified
as being associated with resistance to rifampicin, isoniazid, or fluoroquinolones were consid-
ered to be conferring true resistance, even if phenotypic testing showed susceptibility. Labora-
tory methods have been published in detail elsewhere [11,21], and whole genome sequencing
data are available on the Sequence Read Archive of the National Center for Biotechnology
Information (https://www.ncbi.nlm.nih.gov/sra) as recalibrated BAM files (accession number
SRP128089).
Statistical analysis
Using the most recent year of data available from the 17-year period from 2002 to 2018, the
proportions of new and previously treated TB cases with resistance to anti-TB medicines were
estimated for each country, for the 6 WHO regions, and globally for the following 3 resistance
patterns: (i) isoniazid resistance without rifampicin resistance (Hr-TB), (ii) any isoniazid resis-
tance, and (iii) concurrent isoniazid and rifampicin resistance (MDR-TB). Weights corre-
sponding to the number of notified new and previously treated pulmonary TB cases in each
country in 2017 were applied [1]. The distributional shape of the data was captured in violin
plots. Countries without data for both rifampicin and isoniazid were excluded from global and
regional estimations.
The prevalence of resistance to levofloxacin (from phenotypic testing, adjusted by sequenc-
ing) and pyrazinamide (from sequencing) was calculated for new and previously treated Hr-
TB cases in Azerbaijan, Bangladesh, Belarus, Pakistan, the Philippines, and South Africa. For
isolates from countries with whole genome sequencing data (i.e., Azerbaijan, Bangladesh, Bela-
rus, South Africa, Ukraine, and a subset of the Pakistan isolates), the frequency of mutations
known to confer resistance to isoniazid was calculated among samples displaying either phe-
notypic and/or genotypic isoniazid resistance.
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Results
Epidemiological data
Isoniazid data were available from 156 countries or territories for 211,753 pulmonary TB
patients from 2002 to 2018 (S1 Data). Global maps of the prevalence of resistance among new
cases are shown in Fig 1 and for previously treated cases in Fig 2. Among the countries and ter-
ritories for which data were available, the global prevalence of Hr-TB was 7.4% (95% CI 6.5%–
8.4%) among new TB patients, 11.4% (95% CI 9.4%–13.4%) among previously treated TB
patients (Table 1), and 8.4% (95% CI 7.5%–9.2%) among all TB patients. The distributions of
the national prevalence of Hr-TB and MDR-TB displayed significant variance within each
WHO region (Fig 3). The difference in the median prevalence of Hr-TB for new compared to
previously treated cases was smaller for Hr-TB than for MDR-TB across all regions (S2 Data).
Globally, the prevalence of any resistance to isoniazid—regardless of rifampicin resistance sta-
tus—was 10.7% (95% CI 9.6%–11.9%) among new TB patients and 27.2% (95% CI 24.6%–
29.9%) among previously treated TB patients (Table 1).
Among Hr-TB cases, the prevalence of resistance to either levofloxacin or pyrazinamide
was low (Table 2). An exception was Pakistan, where 12.6% of new Hr-TB patients had resis-
tance to at least one of these drugs. There were no cases of resistance to both drugs among new
Hr-TB patients in Azerbaijan, Bangladesh, Pakistan, or South Africa. In the Philippines, 1.8%
(95% CI 0.2%–6.4%) of new Hr-TB patients had resistance to both drugs. In Belarus, 5.6%
(95% CI 0.1%–27.3%) of new Hr-TB patients had resistance to both drugs, but the sample size
was small (only 19 new Hr-TB cases).
Molecular analyses
Whole genome sequencing data were available from culture isolates from 4,795 patients from
6 countries (Azerbaijan, Bangladesh, Belarus, Pakistan, Ukraine and South Africa) [21]. Of
these, 4,564 had complete coverage of all genomic regions involved in mechanisms of resis-
tance to isoniazid, and 4,559 also had phenotypic testing results available. Of these 4,559
patients, 1,174 were isoniazid resistant by either phenotypic testing or sequencing (S3 Data).
According to the established framework for mutation classification [20], high confidence resis-
tance-conferring mutations were identified in the katG gene in 923 (78.6%, 95% CI 76.1%–
80.9%) of isoniazid-resistant isolates, all occurring at codon 315 (Ser315Asn or Ser315Thr).
For 751 (64%, 95% CI 61.1%–66.7%) of isoniazid-resistant isolates, these mutations occurred
in the katG gene alone, while 172 (14.6%, 95% CI 12.7%–16.8%) of isoniazid-resistant isolates
had concurrent resistance-conferring mutations in the inhA promoter region. Resistance-con-
ferring mutations in the inhA promoter region alone were detected in an additional 80 (6.8%,
95% CI 5.4%–8.4%) isoniazid-resistant isolates, all of which were c-15t. Among the 1,174 iso-
lates that were isoniazid resistant by either phenotypic testing or sequencing, mutations that
were not yet graded as being associated with resistance according to the established framework
—but have nonetheless been previously reported among phenotypically resistant strains—
were identified in 109 patients (9.3%, 95% CI 7.7%–11.1%). Such mutations were found in the
inhA promoter and coding, katG coding, fabG coding, or ahpC promoter regions. For 52 iso-
lates (4.4%; 95% CI 3.3%–5.8%), these mutations occurred in in the absence of any other
graded mutations.
Discussion
In this study, we used aggregated data reported to WHO from 156 countries or territories in
2002–2018 to estimate the prevalence of Hr-TB among new and previously treated TB patients.
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For 6 countries (Azerbaijan, Bangladesh, Belarus, Pakistan, the Philippines, and South Africa)
with results from further phenotypic drug susceptibility testing as well as data from whole
genome or targeted sequencing, the prevalence of resistance to pyrazinamide and levofloxacin
was estimated among Hr-TB patients. For 6 countries with whole genome sequencing data
(Azerbaijan, Bangladesh, Belarus, Pakistan, South Africa and Ukraine), molecular markers of
isoniazid resistance were investigated.
Among countries for which data were available in our study, the global prevalence of Hr-
TB among new cases was 7.4% (95% CI 6.5%–8.4%) and among previously treated cases was
11.4% (95% CI 9.4%–13.4%). The wide variability in the prevalence of Hr-TB and MDR-TB
between countries within the same region highlights the important, yet poorly understood,
role of setting-specific factors on the emergence and spread of rifampicin and isoniazid resis-
tance. Potential associations with HIV could not be explored, as these data were not available.
The prevalence of Hr-TB in our study is higher than the global estimate of the prevalence of
rifampicin resistance, which includes MDR-TB [1]. Given the lower and narrower confidence
bounds around the prevalence estimate for Hr-TB, a history of previous treatment may be less
important when screening for potential Hr-TB as opposed to rifampicin-resistant TB.
To our knowledge, this study represents the first multicountry assessment of resistance to
other TB medicines among over 1,000 Hr-TB patients and provides further justification for
the recommended treatment regimen. There were no cases of combined resistance to pyrazi-
namide and levofloxacin among new Hr-TB patients in Azerbaijan, Bangladesh, Pakistan, the
Philippines, or South Africa, although the prevalence of resistance to each drug varied between
settings. In Pakistan, the prevalence of levofloxacin resistance (10.1% among new cases, 95%
CI 6.7%–13.4%) was alarmingly high compared to the prevalence of rifampicin resistance
Fig 1. Prevalence of Hr-TB among new TB cases. These maps were created using the R package, “whomap.” Hr-TB, isoniazid-resistant, rifampicin-
susceptible TB; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003008.g001
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(4.2% among new cases, 95% CI 3.2%–5.3%) [11]. This likely relates to the indiscriminate use
of fluoroquinolones for the treatment of TB as well as pneumonia and uncomplicated respira-
tory tract infections. Patients with resistance to levofloxacin may require an individually tai-
lored regimen.
Diagnosing people with Hr-TB remains a challenge. A large number of TB patients eligible
for the modified treatment regimen for Hr-TB recommended by WHO in 2018 [8] are missed
by current algorithms for drug susceptibility testing. In many countries, diagnostic algorithms
are driven by the combined testing for TB and rifampicin resistance offered by the GeneXpert
(Cepheid, CA, US) platform, which allows rapid molecular testing at decentralized levels.
Rifampicin testing is used as an initial screening tool to identify patients requiring further
Fig 2. Prevalence of Hr-TB among previously treated TB cases. These maps were created using the R package, “whomap.” Hr-TB, isoniazid-resistant,
rifampicin-susceptible TB; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003008.g002
Table 1. Prevalence (%) of isoniazid resistance among new and previously treated TB cases by WHO region.
Isoniazid resistance without rifampicin resistance (Hr-TB) Any isoniazid resistance
WHO region New Previously treated New Previously treated
Africa 4.5 (3.5–5.5) 6.3 (3.1–10.4) 6.4 (5.2–7.6) 13.5 (8.8–19.0)
Americas 5.0 (4.1–6.1) 7.6 (5.3–10.3) 8.0 (6.9–9.2) 22.8 (28.9–36.8)
Eastern Mediterranean 7.2 (5.8–8.7) 6.3 (3.3–10.2) 10.7 (9.1–12.5) 23.5 (17.8–29.7)
European 4.9 (3.7–6.2) 15.3 (13.9–16.8) 25.4 (24.0–26.7) 47.4 (45.4–49.3)
Southeast Asian 7.6 (6.6–8.6) 12.6 (11.1–14.3) 10.3 (9.2–11.4) 25.7 (23.7–27.8)
Western Pacific 8.8 (8.0–9.6) 11.5 (7.4–16.4) 12.9 (12.0–13.9) 33.9 (27.9–40.2)
Global 7.4 (6.5–8.4) 11.4 (9.4–13.4) 10.7 (9.6–11.9) 27.2 (24.6–29.9)
Abbreviations: Hr-TB, isoniazid-resistant, rifampicin-susceptible TB; TB, tuberculosis; WHO, World Health Organisation
https://doi.org/10.1371/journal.pmed.1003008.t001
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Fig 3. Prevalence (%) of Hr-TB and MDR-TB among new and previously treated TB cases by WHO region. The
median national prevalence within each region is indicated by a horizontal line. AFR, African Region; AMR, American
Region; EMR, Eastern Mediterranean Region; EURO, European Region; Hr-TB, isoniazid-resistant, rifampicin-susceptible
TB; MDR, multidrug-resistant TB; SEAR, Southeast Asian Region; TB, tuberculosis; WPR, Western Pacific Region.
https://doi.org/10.1371/journal.pmed.1003008.g003
Table 2. Prevalence of resistance to levofloxacin and pyrazinamide among new and previously treated isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) cases.
Azerbaijan Bangladesh Belarus (city of Minsk) Pakistan Philippines South Africa (Gauteng) South Africa (KwaZulu Natal)
Levofloxacin 1.5 mg/L
New 0/60, 0% 0/37, 0% 1/19, 5.3% 13/112, 11.6% 0/165, 0% 0/39, 0% 0/19, 0%
(0%–6.0%) (0%–9.5%) (0.1%–26.0%) (6.3%–19.0%) (0%–2.2%) (0%–9.0%) (0%–17.6%)
Previously treated 2/44, 4.5% 0/10, 0% 1/2, 50% 4/14, 28.6% 0/29, 0% 0/10, 0% 0/14, 0%
(0.6%–15.5%) (0%–30.8%) (1.3%–98.7%) (8.4%–58.1%) (0%–11.9%) (0%–30.8%) (0%–23.2%)
Pyrazinamide (pncA sequencing)
New 3/62, 4.8% 0/38, 0% 1/20, 5.0% 1/111, 0.9% 2/111, 1.8% 0/37, 0% 0/19, 0%
(1.0%–13.5%) (0%–9.3%) (0.1%–24.9%) (0%–4.9%) (0.2%–6.4%) (0%–9.5%) (0%–17.6%)
Previously treated 3/43, 7.0% 0/10, 0% 1/3, 33.3% 0/13, 0% 1/9, 11.1% 0/10, 0% 0/14, 0%
(1.5%–19.1%) (0%–30.8%) (0.8%–90.6%) (0%–24.7%) (0.3%–48.2%) (0%–30.8%) (0%–23.2%)
Any resistance to levofloxacin 1.5 mg/L or pyrazinamide (pncA sequencing)
New 3/60, 5.0% 0/37, 0% 1/19, 5.3% 14/111, 12.6% 2/110, 1.8% 0/35, 0% 0/19, 0%
(1.0%–13.9%) (0%–9.5%) (0.1%–26.0%) (7.0%–20.3%) (0.2%–6.4%) (0%–10.0%) (0%–17.6%)
Previously treated 3/43, 7.0% 0/10, 0% 1/2, 50% 4/13, 30.8% 1/9, 11.1% 0/10, 0% 0/14, 0%
(1.5%–19.1%) (0%–30.8%) (1.3%–98.7%) (9.1%–61.4%) (0.3%–48.2%) (0%–30.8%) (0%–23.2%)
Combined resistance to levofloxacin 1.5 mg/L and pyrazinamide (pncA sequencing)
New 0/60, 0% 0/37, 0% 1/19, 5.3% 0/111, 0% 0/110, 0% 0/35, 0% 0/19, 0%
(0%–6.0%) (0%–9.5%) (0.1%–26.0%) (0%–3.3%) (0%–3.3%) (0%–10.0%) (0%–17.6%)
Previously treated 1/43, 2.3% 0/10, 0% 1/2, 50.0% 0/13, 0% 0/9, 0% 0/10, 0% 0/14, 0%
(0.1%–12.3%) (0%–30.8%) (1.3%–98.7%) (0%–24.7%) (0%–33.6%) (0%–30.8%) (0%–23.2%)
Data shown are number of patients resistant divided by number tested, proportion resistant (%) (95% confidence interval).
Abbreviations: Hr-TB, isoniazid-resistant, rifampicin-susceptible TB; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1003008.t002
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drug susceptibility testing and those for whom a rifampicin-resistant TB treatment regimen is
indicated [3]. While the use of this technology is justified, the absence of a similar tool to detect
Hr-TB means that a proportion of TB patients may continue to receive suboptimal first-line
regimens, experience poorer treatment outcomes, and develop further resistance to other
drugs. Line probe assays, such as the WHO-endorsed Hain MDRTBplus (Hain Lifesciences,
Nehren, Germany) and the Nipro NTM+MDRTBII (Nipro, Osaka, Japan), reliably detect
mutations in the katG gene and inhA promoter region, which account for more than 85% of
isoniazid-resistant cases in our dataset. Therefore, while tests with good accuracy do already
exist, they cannot be easily integrated into routine diagnostic algorithms in many countries.
The development of a simple, rapid, accurate, and affordable test to detect isoniazid resistance
at the peripheral level is urgently required. Encouragingly, the TB diagnostic landscape contin-
ues to expand, and several promising technologies are currently in the development or evalua-
tion phase [22].
To better understand the role of mutations in conferring isoniazid resistance, more data are
needed from next generation sequencing and phenotypic testing. Double mutants (the pres-
ence of resistance-conferring mutations in codon 315 of the katG gene and in the inhA pro-
moter region) are known to display high-level resistance to isoniazid [23]. Among isolates
with whole genome sequencing data for extended isoniazid targets, only 14.6% (95% CI
12.7%–16.8%) of 1,174 isolates with either phenotypic and/or genotypic resistance were double
mutants. However, an additional 64% of the 1,174 isolates had mutations in codon 315 of the
katG gene (alone or in the presence of an ungraded mutation in the inhA promoter), which
confers at least a moderate level of resistance. For patients with moderate or high levels of
resistance (78.6%, 95% CI 76.1%–80.9%), increasing the dose of isoniazid is likely not an
option. However, when specific inhA promoter mutations are detected in the absence of
codon 315 katG mutations, in vitro evidence suggests that increasing the dose of isoniazid may
be effective [8]. This may be appropriate for 6.8% (95% CI 5.4%–8.4%) of isoniazid-resistant
patients in our dataset. Mutations that have not been graded in the adopted system may indeed
confer resistance, but current evidence is insufficient to demonstrate a statistically significant
association. Ungraded mutations were detected in 9.3% (95% CI 7.7%–11.1%) of isoniazid-
resistant isolates. Some of these isolates also had concurrent graded mutations, or other
ungraded mutations that are still detected by the line probe assay (e.g., inhA promoter −8
region). Some patients risk being incorrectly classified as having isoniazid-susceptible TB, or
as having only low-level isoniazid resistance if other mutations are present in the inhA pro-
moter region [24].
Our analysis has 3 main limitations. First, it was based primarily on aggregated, cross-sec-
tional data, rather than individual case-based data, from 2 different sources. Countries without
available data were excluded from the analysis. Periodic surveys may have more robust quality
management systems than routine continuous surveillance, and therefore these data may have
less risk of bias. To improve data quality and allow an analysis of trends over time, countries
should move towards establishing electronic, case-based recording and reporting surveillance
systems for TB coupled with quality-assured laboratory testing. Second, although case-based
data were available for 7 high–TB-burden countries from different epidemiological settings,
they were not linked to information about treatment regimens or outcomes, which could have
allowed a better understanding of their clinical relevance. Third, the quality of phenotypic and
genotypic testing for rifampicin and isoniazid may vary between countries, resulting in mis-
classification of cases, which could bias estimates of the prevalence of resistance. The critical
concentrations used for phenotypic testing of levofloxacin was higher than the concentration
now recommended by WHO in new guidance issued in 2018 [19]. However, possible underes-
timation of levels of resistance was mitigated by taking into account the sequencing results
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when classifying isolates as resistant or susceptible. The framework for classification of
detected mutations continues to be regularly updated using the latest available data.
Conclusion
Isoniazid-resistant TB poses a challenge to global efforts for ending the TB epidemic by 2030.
This study shows that many patients with Hr-TB would be missed by current diagnostic algo-
rithms driven by rifampicin testing, highlighting the need for new rapid molecular technolo-
gies to ensure access to appropriate treatment and care. The low prevalence of resistance to
pyrazinamide and fluoroquinolones among patients with Hr-TB provides further justification
for the recommended modified treatment regimen. The analysis of drug resistance patterns
should ideally be linked to patient treatment outcome data, to better understand the clinical
relevance of laboratory testing results and contribute to global policy for clinical decision-
making.
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